Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/23/2026 | $10.00 | Outperform | Oppenheimer |
| 9/4/2025 | Hold → Buy | Maxim Group | |
| 8/16/2024 | $4.00 → $1.50 | Buy → Neutral | UBS |
| 11/17/2023 | $11.00 | Outperform | Robert W. Baird |
| 11/8/2023 | Buy → Hold | Maxim Group | |
| 7/24/2023 | $12.00 | Buy | Citigroup |
| 5/1/2023 | $24.00 | Buy | Truist |
| 3/28/2023 | $11.00 | Neutral → Buy | UBS |
Submission status for COHERUS BIOSCIENCES INC's drug CIMERLI (SUPPL-5) with active ingredient RANIBIZUMAB-EQRN has changed to 'Approval' on 05/21/2024. Application Category: BLA, Application Number: 761165, Application Classification:
Submission status for COHERUS BIOSCIENCES INC's drug LOQTORZI (SUPPL-1) with active ingredient TORIPALIMAB-TPZI has changed to 'Approval' on 04/22/2024. Application Category: BLA, Application Number: 761240, Application Classification:
Submission status for COHERUS BIOSCIENCES INC's drug UDENYCA (SUPPL-15) with active ingredient PEGFILGRASTIM-CBQV has changed to 'Approval' on 12/22/2023. Application Category: BLA, Application Number: 761039, Application Classification:
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Jan. 27, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – The global oncology therapy market is charging toward a massive $668 billion valuation by 2034, as a ruthless capital rotation finally rewards execution-ready platforms over the "hopes and dreams" of speculative discovery assets[1]. With the FDA's accelerated approval pathway delivering survival wins across 65% of solid tumor indications, the 2026 regulatory landscape is demanding a new breed of registration-directed study designs that prioritize raw objective response rates and durability[2]. This structural shift creates an asymmetric investment window for Oncolytic
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Jan. 16, 2026 /PRNewswire/ -- Equity Insider News Commentary – The precision medicine sector is undergoing a structural realignment toward platform-based biologics, as the market prepares to surge from $138 billion this year to over $537 billion by 2035[1]. This shift marks the end of "one-size-fits-all" treatments, as investors rotate capital into modular systems designed to hunt multiple cancer targets at once. This secular transition is creating massive opportunities for specialized platforms that can scale across high-prevalence killers like lung, breast, and pancreatic cancers, led by GT Biopharma, Inc. (NASDAQ:GTBP), ImmunityBio (NA
VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants confront a looming $170 billion patent cliff[1]. This massive pressure is forcing a strategic capital rotation toward late-stage, registration-ready oncology platforms that can be delivered with biologic-like manufacturing efficiency. With blockbuster drugs losing exclusivity through 2030, the precision oncology market is projected to reach $225.65 billion by 2032[2] as buyers aggressively target scalable technologies. This industry-wide shift into proprietary precision platforms fuels the 2026
8-K - Coherus Oncology, Inc. (0001512762) (Filer)
424B5 - Coherus Oncology, Inc. (0001512762) (Filer)
8-K - Coherus Oncology, Inc. (0001512762) (Filer)
Oppenheimer initiated coverage of Coherus BioSciences with a rating of Outperform and set a new price target of $10.00
Maxim Group upgraded Coherus BioSciences from Hold to Buy
UBS downgraded Coherus BioSciences from Buy to Neutral and set a new price target of $1.50 from $4.00 previously
4 - Coherus Oncology, Inc. (0001512762) (Issuer)
4 - Coherus Oncology, Inc. (0001512762) (Issuer)
4 - Coherus Oncology, Inc. (0001512762) (Issuer)
ALISO VIEJO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a late-stage biopharmaceutical company, today announced the appointment of Jean-Frédéric Viret, Ph.D., as the company's Chief Financial Officer (CFO). Dr. Viret brings over two decades of corporate finance experience in the life sciences industry, leading companies from early-stage clinical development through post-commercialization. At SpyGlass, he will lead the finance and accounting functions as the company advances the Bimatoprost Drug Pad-IOL System (BIM-IOL System) toward late-stage development and potential commercialization. "We are excited to welcome Jean to SpyGlass Pharma as we continue to advance our clin
– Responsible for Corporate Development, Investor Relations, Government Affairs – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that Arvind Sood has joined the Company as Chief Strategy and Corporate Affairs Officer reporting to Denny Lanfear, Chairman and Chief Executive Officer. Mr. Sood's responsibilities include key externally facing and strategic functions. "We are thrilled to have a such a well-regarded senior biotechnology executive join us as we advance our innovative, next generation cancer therapeutics and drive LOQTORZI® revenues in nasopharyngeal carcinoma," said Denny Lanfear, Coherus Oncology Chairman and Chief
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus or the Company, NASDAQ:CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice President (SVP) and Global Controller for Merck & Co., Inc., (Merck) was appointed to its Board of Directors effective May 31, 2024. Ms. Karachun has nearly four decades of experience leading finance, accounting, and SEC reporting functions at multi-billion-dollar global companies. Her experience includes more than 17 years at Merck, where she held positions of increasing financial management responsibility. As Global Controller at Merck, Ms. Karachun managed a global team responsible for all accou
– CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer – – Q3 2025 ending cash, cash equivalents and marketable securities of $191.7 million – – LOQTORZI® net revenue was $11.2 million, a 12% increase over Q2 2025 – – Conference call today at 5:00 p.m. Eastern Standard Time – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today reported financial results for the third quarter ended September 30, 2025 and provided an overview of recent business highlights. "In Q3 2025, we gained significant momentum on our strategy to develop innovative oncology therapies that substantially increase patient sur
REDWOOD CITY, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its third quarter 2025 financial results will be released after market close on Thursday, November 6, 2025. Starting at 5:00 p.m. Eastern Time on November 6, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Thursday, November 6, 2025, starting at 5:00 p.m. Eastern Standard Time To access the conference call, please pre-register thr
– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – – Q2 2025 ending cash, cash equivalents and marketable securities of $238 million – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today reported financial results for the second quarter ended June 30, 2025 and provided an overview of recent business highlights. "Coherus Oncology is dedicated to significantly extending survival for people with cancer," said Denny Lanfear, Coherus Chairman and Chief Executive Officer. "We are execu
SC 13G - Coherus BioSciences, Inc. (0001512762) (Subject)
SC 13G/A - Coherus BioSciences, Inc. (0001512762) (Subject)
SC 13G/A - Coherus BioSciences, Inc. (0001512762) (Subject)